SI Bone is projected to record more than $200 million in worldwide revenue during fiscal year 2025, according to preliminary ...

Jim Cramer’s repeated description of SI-BONE (SIBN) as a “great, great speculation,” combined with fresh buy-side analyst ...

Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20%SANTA CLARA, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in ...

Maheshwari announced, "We're updating our full year revenue guidance to range between $198 million to $200 million. This implies year-over-year growth of approximately 18% to 20% as compared to the ...

SI-BONE reports strong revenue growth and improved financial metrics for Q4 2024 and FY 2024, achieving positive adjusted EBITDA. SI-BONE, Inc. reported strong financial results for the fourth quarter ...

SANTA CLARA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today ...

SI-Bone shares rose in after-hours trading as three executives sold stock last week to cover RSU tax obligations.

SI-BONE, Inc., a company focused on medical technologies for sacropelvic disorders, announced it will release its financial results for the fourth quarter and full year of 2024 on February 24, 2025, ...

SANTA CLARA, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (SIBN), a Silicon Valley-based medical device company focused on sacropelvic surgical solutions, today confirmed that certain CD ...

SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone ...